

## Tips from our Protein Separation ZenMasters

# N-Glycan Analysis





Chad Eichman, Ph.D.  
BioPharm Global Marketing Manager

**I'm working with mAbs and looking at common fucosylated, neutral biantennary glycans. Most of the methods I see are for the Human IgG library - the glycosylation patterns I see are nowhere near this complex, where do I start?**

There are typically favorable glycosylation profiles; depending on the desired effect of the therapeutic, glycosylation strongly influences efficacy, clearance, and even immunogenicity.<sup>1</sup> As such, it is critical to monitor several key glycans, including high mannose (Man-5, Man-6) depending on the cell line used. High mannose tends to improve clearance. Others to monitor include afucosylated glycans for effector function, and sialylated glycans which affect antibody dependent cell cytotoxicity (ADCC), amongst other things.<sup>2</sup> Moreover, "critical pairs" for a mAb expressed in one cell line, purified by a method, will be completely different than another mAb expressed in the same cell line.

Although methods reported for Human IgG library are a good starting point, for robust methods, care should be taken into gradient optimization to separate out critical pairs. In most instances, separation of high mannose species from afucosylated glycans (e.g. Man-5 and G0), in addition to isomers (G1F(3) and G1F(6)) are most common. Of course, selection of a selective stationary phase is also critical.

### 2-AB Labeled Glycans from Standard Solution



#### Conditions for both columns:

Column:	bioZen 2.6 µm Glycan
Dimensions:	100 x 2.1 mm
Part No.:	00D-4773-AN
Mobile Phase:	A: 100 mM Ammonium Formate, pH 4.5 B: Acetonitrile
Gradient:	Time (min) % B
	0 76
	16 72
	25.9 40
	27.2 40
	27.3 76
	30 76

Flow Rate: As noted

Temperature: 50 °C

Detection: FLD ex/em 330/420 nm

Sample: Human IgG Glycan Library

# N-Glycan Analysis



**Chad Eichman, Ph.D.**  
BioPharm Global Marketing Manager

### How do I look at terminal sialic acid for my glycoprotein? Better yet, can I use one column for sialylated glycans and neutral, biantennary glycans?

Sialylated glycans are of critical importance for fusion proteins and clearance, reduced ADCC for mAbs, and anti-inflammatory effects for immunotherapy applications.<sup>2</sup> Further, some biotherapeutics such as recombinant erythropoietin is heavily glycosylated, with much more complexity and sialylation than mAbs which are typically only mono- or di-sialylated.

Depending on the column chemistry used, HILIC may not give the proper selectivity of different sialylated glycans. Alternatively, a mixed-mode anion-exchange column or DMB labeling might be necessary.

However, when using a phase chemistry with good selectivity for sialylated glycans adjustment of the gradient might be necessary for tri- and tetra-antennary glycans. With this adjustment, most sialylated glycans can be separated. MS can then be used for identification of N-glycolneuraminic acid and N-acetyneuraminic acid, the former being found in non-human mammals with the potential of immunogenicity.

1. Higel, F.; Seidl, A.; Sorgel, F.; Fiess, W. "N-Glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins." *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 100, 2016, pp. 94–100., doi:10.1016/j.ejpb.2016.01.005.

2. Liu, L. "Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins." *Journal of Pharmaceutical Sciences*, vol. 104, no. 6, 2015, pp. 1866–1884., doi:10.1002/jps.24444

# Product Ordering Information

## bioZen™ Products - Powered by Biocompatible Hardware

bioZen Columns (mm)	Phases							Biocompatible Guard Cartridges*	
	50 x 2.1	100 x 2.1	150 x 2.1	250 x 2.1	50 x 4.6	150 x 4.6	300 x 4.6	for 2.1 mm	for 4.6 mm
bioZen 2.6 µm Glycan	—	00D-4773-AN	00F-4773-AN	—	—	—	—	AJO-9800	—
bioZen 1.6 µm Peptide PS-C18	00B-4770-AN	—	00F-4770-AN	—	—	—	—	AJO-9803	—
bioZen 3 µm Peptide PS-C18	—	—	—	—	00B-4771-E0	00F-4771-E0	—	—	AJO-7606
bioZen 1.7 µm Peptide XB-C18	00B-4774-AN	—	00F-4774-AN	—	—	—	—	AJO-9806	—
bioZen 2.6 µm Peptide XB-C18	00B-4768-AN	—	00F-4768-AN	00G-4768-AN	00B-4768-E0	00F-4768-E0	—	AJO-9806	AJO-9808
bioZen 3.6 µm Intact C4	00B-4767-AN	—	00F-4767-AN	—	00B-4767-E0	00F-4767-E0	—	AJO-9809	AJO-9811
bioZen 3.6 µm Intact XB-C8	00B-4766-AN	—	00F-4766-AN	—	00B-4766-E0	00F-4766-E0	—	AJO-9812	AJO-9814
bioZen 1.8 µm SEC-2	—	—	—	—	—	00F-4769-E0	00H-4769-E0	—	AJO-9850
bioZen 1.8 µm SEC-3	—	—	—	—	—	00F-4772-E0	00H-4772-E0	—	AJO-9851

\*AJO-7606 requires guard holder KJO-4282. All other guard cartridges require guard holder AJO-9000.



**Have Questions? Visit:**  
[www.phenomenex.com/bioZen](http://www.phenomenex.com/bioZen)  
**We're here to help!**

**guarantee**

If bioZen columns in this technical note do not provide at least equivalent separations as compared to a competing column of the same phase, particle size, and dimensions, return the column with the comparative data within 45 days for a FULL REFUND.

### Australia

t: +61 (0)2-9428-6444  
 f: +61 (0)2-9428-6445  
 auinfo@phenomenex.com

### Austria

t: +43 (0)1-319-1301  
 f: +43 (0)1-319-1300  
 anfrage@phenomenex.com

### Belgium

t: +32 (0)2 503 4015 (French)  
 t: +32 (0)2 511 8666 (Dutch)  
 f: +31 (0)30-2383749  
 beinfo@phenomenex.com

### Canada

t: +1 (800) 543-3681  
 f: +1 (310) 328-7768  
 info@phenomenex.com

### China

t: +86 400-606-8099  
 f: +86 (0)22 2532-1033  
 phen@agela.com

### Denmark

t: +45 4824 8048  
 f: +45 4810 6265  
 nordicinfo@phenomenex.com

### Finland

t: +358 (0)9 4789 0063  
 f: +45 4810 6265  
 nordicinfo@phenomenex.com

### France

t: +33 (0)1 30 09 21 10  
 f: +33 (0)1 30 09 21 11  
 franceinfo@phenomenex.com

### Germany

t: +49 (0)6021-58830-0  
 f: +49 (0)6021-58830-11  
 anfrage@phenomenex.com

### India

t: +91 (0)40-3012 2400  
 f: +91 (0)40-3012 2411  
 indiainfo@phenomenex.com

### Ireland

t: +353 (0)1 247 5405  
 f: +44 1625-501796  
 eireinfo@phenomenex.com

### Italy

t: +39 051 6327511  
 f: +39 051 6327555  
 italiainfo@phenomenex.com

### Luxembourg

t: +31 (0)30-2418700  
 f: +31 (0)30-2383749  
 nlinfo@phenomenex.com

### Mexico

t: 01-800-844-5226  
 f: 001-310-328-7768  
 tecnicomx@phenomenex.com

### The Netherlands

t: +31 (0)30-2418700  
 f: +31 (0)30-2383749  
 nlinfo@phenomenex.com

### New Zealand

t: +64 (0)9-4780951  
 f: +64 (0)9-4780952  
 nzinfo@phenomenex.com

### Norway

t: +47 810 02 005  
 f: +45 4810 6265  
 nordicinfo@phenomenex.com

### Portugal

t: +351 221 450 488  
 f: +34 91-413-2290  
 ptinfo@phenomenex.com

### Spain

t: +34 91-413-8613  
 f: +34 91-413-2290  
 espinfo@phenomenex.com

### Sweden

t: +46 (0)8 611 6950  
 f: +45 4810 6265  
 nordicinfo@phenomenex.com

### Switzerland

t: +41 61 692 20 20  
 f: +41 61 692 20 22  
 swissinfo@phenomenex.com

### United Kingdom

t: +44 (0)1625-501367  
 f: +44 (0)1625-501796  
 ukinfo@phenomenex.com

### USA

t: +1 (310) 212-0555  
 f: +1 (310) 328-7768  
 info@phenomenex.com

### All other countries Corporate Office USA

t: +1 (310) 212-0555  
 f: +1 (310) 328-7768  
 info@phenomenex.com

### Terms and Conditions

Subject to Phenomenex Standard Terms & Conditions, which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

### Trademarks

bioZen is a trademark of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2018 Phenomenex, Inc. All rights reserved.

